The institute announced data from the Phase III ACTT study, which showed a statistically significant improvement in time to recovery for remdesivir compared with placebo. There was also a suggestion of survival benefit that barely missed statistical significance. An analyst said the drug could be a first-line treatment.

LEAVE A REPLY

Please enter your comment!
Please enter your name here